Life Sciences Antitrust: Recent European Commission Enforcement and Trends

The European Commission appears to be advancing a more expansive antitrust agenda in life sciences — one increasingly focused on innovation, exclusionary conduct and strategic interference with future competition. Counsel Michael Frese and European counsel Georgios Zacharodimos discuss how recent cases highlight the EC's efforts to prevent innovation suppression, unfair practices and anticompetitive conduct across the pharmaceutical sector, where merger reviews, abuse investigations and cartel enforcement are reshaping industry dynamics.